Optimvia — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Optimvia is a private, pre-revenue biotech founded in 2021, headquartered in San Francisco, CA. The company has developed the ADEPT Platform, a computational protein engineering platform, to design novel enzymes and cofactors for synthesizing therapeutics. Its lead program is a biosynthetic heparin, targeting the multi-billion dollar anticoagulant market to replace the current animal-derived supply. The company has established a key partnership with Ginkgo Bioworks to scale manufacturing and is led by a board with expertise in pharmaceuticals, Nobel Prize-winning science, and AI.

AnticoagulationThrombosis

Technology Platform

ADEPT Platform (Advanced Design of Protein Therapeutics): A computational protein engineering platform used to design novel amino acid sequences for enzymes and cofactors to synthesize complex therapeutic molecules.

Opportunities

The primary opportunity is to replace the entire global animal-derived heparin market with a safer, more reliable, and scalable biosynthetic version, addressing a critical supply chain vulnerability.

Success with heparin also validates the ADEPT Platform for engineering synthesis pathways for other complex, high-value therapeutic molecules, creating a pipeline of novel biologics.

Risk Factors

Key risks include the technical challenge of scaling a complex multi-enzyme synthesis process to be cost-competitive, navigating an uncertain regulatory pathway for a biosynthetic version of a complex natural product, and overcoming commercial inertia to switch from an established, low-cost animal-derived supply.

Competitive Landscape

Competition includes other biotech firms developing bioengineered or synthetic heparin alternatives, as well as potential efforts from large pharmaceutical companies with expertise in anticoagulants. The competitive edge lies in achieving a scalable, economically viable enzymatic synthesis process and establishing first-mover advantage in replacing the animal-derived supply.

More companies in Biologics / Biosimilars →More companies in United States →